Cytokine traps block cytokine action in vivo. We first evaluated the in vivo activity of the human IL-1 trap by testing its ability to block the biological actions of human IL-1β administered SC ...

During early drug development and preclinical development, researchers use in vitro cultured lymphocytes to induce cytokine ...

Understanding cytokine action in acute neurodegeneration could lead to novel and effective therapeutic strategies, some of which are already in clinical trials. Nature Reviews Neuroscience ...

Cytokine actions may be autocrine meaning the cytokine acts on the same cell that secretes it. If the cytokine acts on cells nearby other than the one that secreted it, the action is termed paracrine.

Cytokines are a diverse group of small protein molecules that play crucial roles in the immune system and various biological processes. They are synthesized and secreted by a range of immune cells, ...

Cytokine release syndrome is an immune system response that can occur due to immunotherapy or infection. It happens when an immune system communication protein called cytokine is overproduced.

Cytokine interaction networks drive immune function, but they are difficult to map and study. Not only are these networks complex, but they are built by molecules that typically exist in low ...

Cytokines are powerful regulators of the immune system and attractive therapeutic effector candidates. However, their sites of action must be restricted to avoid systemic toxicity.

One cytokine, two platforms. Synthekine aims to optimize IL-10, ... “Based on emerging external and internal data about non-alpha IL2’s mechanism of action and therapeutic potential, ...

Expert Rev Endocrinol Metab. 2008;3(2):147-159. Inflammatory or immunological factors appear to be implicated in insulin resistance and decreased β-cell function. [37] Compared with nondiabetic ...

Get Instant Summarized Text (Gist) Incorporating interleukin-12 (IL-12) into mRNA vaccines enhances CD8 + T cell responses, improving protection against SARS-CoV-2, influenza, melanoma, and ...

CytoAgents Announces FDA Acceptance of IND Application for CTO1681 to Treat Cytokine Release Syndrome in Oncology Company Closes Financing and Prepares to Launch Phase 1b/2a Clinical Trial May 11 ...